In another cohort of 90 prostate cancer patients and 83 melanoma patients, individuals with metastatic cancer showed significantly higher USP9X levels than individuals with primary cancer and no metastases (melanoma, p < 0.0001; prostate, p = 0.0037) (Supplementary Figure S3K) [60–62]. Here, USP9X is linked to prostate carcinoma.